Physician profile
Michael Bui
NPI 1740919398
$4,532.28
in general payments reported to CMS, 2019-2025
36 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.79 · 2023: $1,912 · 2024: $1,528 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,504.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $768.09 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $370.92 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $289.29 | 2023-2024 | Gvoke Hypopen, Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $237.46 | 2023-2024 | |
| Insulet Corporation | $227.98 | 2023-2025 | Omnipod |
| Cequr Corporation | $218.37 | 2023-2024 | Cequr Simplicity |
| Novo Nordisk INC | $211.61 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Antares Pharma, INC. | $191.57 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Mannkind Corporation | $188.74 | 2023-2024 | Afrezza |
| Merck Sharp & Dohme LLC | $136.96 | 2025 | Keytruda, Keytruda Qlex |
| Amgen INC. | $127.86 | 2024-2025 | Evenity, Prolia, Repatha |
| Radius Health, INC. | $126.07 | 2023-2024 | Tymlos |
| Accord Healthcare, INC. | $124.59 | 2025 | |
| Embecta Corp. | $106.17 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Dexcom, INC. | $100.86 | 2023-2024 | Dexcom G6 Transmitter |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $93.97 | 2025 | Xtandi |
| Janssen Biotech, INC. | $92.40 | 2025 | Erleada |
| Immunitybio, INC. | $90.98 | 2025 | |
| Recordati_rare_diseases_inc. | $76.91 | 2023-2024 | Signifor Lar, Isturisa |
| Tandem Diabetes Care, INC. | $75.88 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $75.35 | 2024-2025 | Interstim, Minimed 780g |
| Teleflex LLC | $72.17 | 2025 | Barrigel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.25 | 2023-2024 | Jardiance |
| Ibsa Pharma INC. | $57.69 | 2023-2024 | Tirosint, Licart, Licart |
| Corcept Therapeutics | $54.81 | 2024 | Korlym |
| Sumitomo Pharma America, INC. | $53.81 | 2025 | Gemtesa |
| Urogen Pharma, INC. | $45.30 | 2025 | |
| Novartis Pharmaceuticals Corporation | $41.89 | 2025 | |
| Tolmar, INC. | $39.82 | 2023-2025 | Eligard |
| Halozyme INC | $36.08 | 2023 | |
| Sanofi-Aventis U.S. LLC | $30.86 | 2023 | |
| Horizon Therapeutics Plc | $26.63 | 2023 | Tepezza |
| Averitas Pharma INC. | $26.25 | 2024 | Qutenza |
| Ascensia Diabetes Care US INC. | $25.04 | 2024 | |
| Amryt Pharma Holdings LTD | $15.71 | 2023 | Mycapssa |
| Amphastar Pharmaceuticals, INC. | $13.94 | 2023 | Baqsimi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.